Takeda (NYSE:TAK) has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use for its enzyme replacement therapy rADAMTS13 for the treatment of cTTP ...

While cTTP represents a tiny patient population for TAK-755, Takeda is also running trials of the drug in other indications, including a phase 2 study in acquired or immune-mediated TTP (iTTP) and ...